Daily Pumpkin Seed Oil Supplementation to Study Effects on Inflammation and Biochemical Markers in Adults Receiving Maintenance Hemodialysis

What this Trial Is About

Patients with end-stage renal disease on maintenance hemodialysis often face chronic inflammation, oxidative stress, and abnormal lipid levels, which contribute to high rates of heart-related illness and death. This trial evaluates pumpkin seed oil, a supplement rich in antioxidants and anti-inflammatory compounds, for its potential to improve clinical and biochemical outcomes in these patients. The study is a randomized, open-label, prospective trial conducted at the Hemodialysis Center, Al-Karama Teaching Hospital in Iraq. Participants are assigned to two groups one receives daily oral pumpkin seed oil capsules 1000 mg for three months alongside their usual hemodialysis care, while the control group continues standard care without the supplement. The intervention aims to assess changes in inflammatory markers IL-6, hsCRP, sVCAM-1, oxidative stress indicators MDA, SOD, and lipid profiles over the treatment period. Throughout the study, participants will have blood tests at the start and after three months to measure these biochemical markers. Researchers will monitor safety and adherence during the treatment period. The studys primary outcomes focus on changes in serum levels of inflammatory and oxidative stress biomarkers, lipid profiles, and antioxidant enzyme activity over the three-month follow-up.

Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients